FDA Expands Artificial Intelligence Capabilities with Agentic AI Deployment

The U.S. Food and Drug Administration today announced the deployment of agentic AI capabilities for all agency employees.  Agentic AI capabilities will enable the creation of more complex AI workflows — harnessing various AI models — to assist with multi-step tasks.  Agentic AI refers to advanced artificial intelligence systems designed to achieve specific goals by planning, reasoning, and executing multi-step actions.  These systems incorporate built-in guidelines — including human oversight —to ensure reliable outcomes.  The tool is entirely optional for FDA staff and is used voluntarily.

“We are diligently expanding our use of AI to put the best possible tools in the hands of our reviewers, scientists and investigators,” said FDA Commissioner Marty Makary, M.D., M.P.H.  “There has never been a better moment in agency history to modernize with tools that can radically improve our ability to accelerate more cures and meaningful treatments.”

In May, the agency deployed an LLM-based tool, Elsa, voluntarily used by more than 70% of staff, according to internal agency data.  Since that initial deployment, FDA program teams have driven frequent modifications to better integrate Elsa into workflows.  Today’s agentic AI deployment will enable FDA staff to further advance the use of AI to assist with more complex tasks, such as meeting management, pre-market reviews, review validation, post-market surveillance, inspections and compliance and administrative functions.  As part of the agentic AI deployment, the agency is launching a two-month Agentic AI Challenge for staff to build Agentic AI solutions and demonstrate them at the FDA Scientific Computing Day in January 2026.

“FDA's talented reviewers have been creative and proactive in deploying AI capabilities — agentic AI will give them a powerful tool to streamline their work and help them ensure the safety and efficacy of regulated products,” said Chief AI Officer Jeremy Walsh.